Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.37 |
| ▸ | KDM4A | O75164 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.32 |
| ▸ | CPB1 | P15086 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203122 | 0.78 | CPB2 (0.33) | KDM5AKDM5BCPB2CPB1 | |
| SCHEMBL7875665 | 0.74 | CPB2 (0.35) | KDM5AKDM5BKDM4AKDM4CCPB2 | |
| SCHEMBL306663 | 0.73 | KDM5A (0.44) | KDM5AKDM5BKDM4AKDM4CKDM2B | |
| SCHEMBL4900683 | 0.71 | CPB2 (0.34) | KDM5AKDM5BKDM4AKDM4CCPB2 | |
| SCHEMBL31285260 | 0.70 | — | — | |
| SCHEMBL7863644 | 0.70 | L3MBTL1 (0.41) | CPB2MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL23320277 | 0.69 | TBXAS1 (0.42) | CPB2CPB1 | |
| SCHEMBL21404585 | 0.68 | CPB2 (0.34) | KDM5AKDM5BKDM2BCPB2CPB1 | |
| SCHEMBL22588363 | 0.68 | ALDH1A1 (0.46) | HTTKMT2A | |
| SCHEMBL16828766 | 0.68 | ALDH1A1 (0.42) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2496557-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | ABCB1, CYP3A7, UGT2B7 | KDM5A 2866/4885KDM5B 1619/4885KDM4A 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.